Mariève Simoncelli1, Johanne Samson2, Jean-François Bussières3, Jacques Lacroix4, Marc Dorais5, Renaldo Battista6, Sylvie Perreault7. 1. BPharm, MSc, is with the Health Technology Assessment Unit, Centre hospitalier universitaire Sainte-Justine, Montréal, Quebec. 2. MSc, is with the Health Technology Assessment Unit, Centre hospitalier universitaire Sainte-Justine, Montréal, Quebec. 3. BPharm, MSc, MBA, FCSHP, is with the Pharmacy Practice Research Unit and the Pharmacy Department, Centre hospitalier universitaire Sainte-Justine, and the Faculty of Pharmacy, Université de Montréal, Montréal, Quebec. 4. MD, FRCPC, FAAP, is with the Department of Pediatrics, Université de Montréal and the Centre hospitalier universitaire Sainte-Justine, Montréal, Quebec. 5. MSc, is with StatSciences Inc, Notre-Dame-de-l'Île-Perrot, Quebec. 6. MD, MPH, ScD, FRCPC, is with the Fonds de recherche du Québec-Santé, Montréal, Quebec. 7. BPharm, PhD, is with the Faculty of Pharmacy, Université de Montréal, Montréal, Quebec.
Abstract
BACKGROUND: Tyrosinemia type I is a rare but severe genetic metabolic disorder. Nitisinone combined with a diet low in tyrosine and phenylalanine became first-line therapy in 1994. OBJECTIVES: To estimate the direct medical costs of health care services related to the treatment of tyrosinemia type I, taking into consideration the real-life efficacy of nitisinone. METHODS: A cost-consequence analysis was performed for all children with a confirmed diagnosis of tyrosinemia type I who were treated in Quebec between January 1, 1984, and January 1, 2009. The costs of care were compared for 3 consecutive historical groups: no nitisinone (1984 to 1994), late intervention with nitisinone (first dose received between 1994 and 1997), and early intervention with nitisinone (first dose received between 1997 and 2008). Data were derived from patient charts, hospital databases, and the Régie de l'assurance maladie du Québec and MED-ÉCHO administrative databases. Costs were reported in 2008 Canadian dollars. RESULTS: Nitisinone treatment was associated with significant reductions in the number and duration of hospital admissions, the number of admissions to a pediatric intensive care unit, and the number of liver transplants. The cost of hospitalization per person-year was significantly lower in the 2 groups treated with nitisinone: $673 and $5 590 for the early-intervention and late-intervention groups, respectively, as compared to $12 980 for the no-nitisinone group (p < 0.001). Hospital costs per person-year for liver transplant were $3 198 for the late-intervention group and $5 044 for the no-nitisinone group: there were no transplants in the early-intervention group. The cost of nitisinone per person-year was $51 493 for the early-intervention group and $64 895 for the late-intervention group. CONCLUSIONS: Nitisinone treatment significantly improved the outcomes of patients with tyrosinemia type I, while decreasing utilization of health care resources, liver transplants, and associated costs.
BACKGROUND:Tyrosinemia type I is a rare but severe genetic metabolic disorder. Nitisinone combined with a diet low in tyrosine and phenylalanine became first-line therapy in 1994. OBJECTIVES: To estimate the direct medical costs of health care services related to the treatment of tyrosinemia type I, taking into consideration the real-life efficacy of nitisinone. METHODS: A cost-consequence analysis was performed for all children with a confirmed diagnosis of tyrosinemia type I who were treated in Quebec between January 1, 1984, and January 1, 2009. The costs of care were compared for 3 consecutive historical groups: no nitisinone (1984 to 1994), late intervention with nitisinone (first dose received between 1994 and 1997), and early intervention with nitisinone (first dose received between 1997 and 2008). Data were derived from patient charts, hospital databases, and the Régie de l'assurance maladie du Québec and MED-ÉCHO administrative databases. Costs were reported in 2008 Canadian dollars. RESULTS:Nitisinone treatment was associated with significant reductions in the number and duration of hospital admissions, the number of admissions to a pediatric intensive care unit, and the number of liver transplants. The cost of hospitalization per person-year was significantly lower in the 2 groups treated with nitisinone: $673 and $5 590 for the early-intervention and late-intervention groups, respectively, as compared to $12 980 for the no-nitisinone group (p < 0.001). Hospital costs per person-year for liver transplant were $3 198 for the late-intervention group and $5 044 for the no-nitisinone group: there were no transplants in the early-intervention group. The cost of nitisinone per person-year was $51 493 for the early-intervention group and $64 895 for the late-intervention group. CONCLUSIONS:Nitisinone treatment significantly improved the outcomes of patients with tyrosinemia type I, while decreasing utilization of health care resources, liver transplants, and associated costs.
Authors: F J van Spronsen; Y Thomasse; G P Smit; J V Leonard; P T Clayton; V Fidler; R Berger; H S Heymans Journal: Hepatology Date: 1994-11 Impact factor: 17.425
Authors: Jean Larochelle; Fernando Alvarez; Jean-François Bussières; Isabelle Chevalier; Louis Dallaire; Josée Dubois; Frédéric Faucher; Daphna Fenyves; Paul Goodyer; André Grenier; Elisabeth Holme; Rachel Laframboise; Marie Lambert; Sven Lindstedt; Bruno Maranda; Serge Melançon; Aicha Merouani; John Mitchell; Guy Parizeault; Luc Pelletier; Véronique Phan; Piero Rinaldo; C Ronald Scott; Charles Scriver; Grant A Mitchell Journal: Mol Genet Metab Date: 2012-07-13 Impact factor: 4.797
Authors: A Masurel-Paulet; J Poggi-Bach; M-O Rolland; O Bernard; N Guffon; D Dobbelaere; J Sarles; H Ogier de Baulny; G Touati Journal: J Inherit Metab Dis Date: 2008-01-25 Impact factor: 4.982
Authors: Caitlin VanLith; Rebekah Guthman; Clara T Nicolas; Kari Allen; Zeji Du; Dong Jin Joo; Scott L Nyberg; Joseph B Lillegard; Raymond D Hickey Journal: Hum Gene Ther Date: 2018-06-22 Impact factor: 5.695
Authors: Raymond D Hickey; Clara T Nicolas; Kari Allen; Shennen Mao; Faysal Elgilani; Jaime Glorioso; Bruce Amiot; Caitlin VanLith; Rebekah Guthman; Zeji Du; Harvey Chen; Cary O Harding; Robert A Kaiser; Scott L Nyberg; Joseph B Lillegard Journal: Cell Transplant Date: 2018-11-26 Impact factor: 4.064
Authors: Maximiliano L Cacicedo; Christine Weinl-Tenbruck; Daniel Frank; Sebastian Wirsching; Beate K Straub; Jana Hauke; Jürgen G Okun; Nigel Horscroft; Julia B Hennermann; Fred Zepp; Frédéric Chevessier-Tünnesen; Stephan Gehring Journal: Mol Ther Methods Clin Dev Date: 2022-07-15 Impact factor: 5.849